Sequence Optimization
Great Bay Bio’s Antibody Discovery & Sequence Optimization Service integrates functional screening with AI-driven AlfaBodY & AlfaDAX platform to deliver lead candidates characterized by both high biological potency and superior manufacturability. By addressing immunogenicity and stability at the sequence level, we reduce the probability of clinical failure and accelerate the transition from discovery to IND.
AlfaDAX Antibody Optimization: End-to-end optimization completed in ~2 months, enabling rapid progression to PCC.
Simultaneous optimization of affinity, humanization, and developability to generate clinical-grade antibodies with high activity, reduced risk, and strong manufacturability.
20+ projects | 83% success rate
Service features
Case Study
● Molecule Optimization
● Non-specific Binding Prediction
AlfaDAX Non-specific Binding Prediction - Accuracy 78%
· 137 approved and late-stage clinical antibodies were predicted by AlfaDAX.
· Non-specific Binding (NSB, positive) was tested by Heparin Affinity Chromatography (HAC), DNA Binding ELISA, Baculovirus Particle (BVP) Binding Assay
● Humanization Enhancement
